KR20210097170A - 유방암을 갖는 여성에서 아베마시클립과 조합된 엘라세스트란트 - Google Patents

유방암을 갖는 여성에서 아베마시클립과 조합된 엘라세스트란트 Download PDF

Info

Publication number
KR20210097170A
KR20210097170A KR1020217020321A KR20217020321A KR20210097170A KR 20210097170 A KR20210097170 A KR 20210097170A KR 1020217020321 A KR1020217020321 A KR 1020217020321A KR 20217020321 A KR20217020321 A KR 20217020321A KR 20210097170 A KR20210097170 A KR 20210097170A
Authority
KR
South Korea
Prior art keywords
patient
abemaciclib
dose
administered
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217020321A
Other languages
English (en)
Korean (ko)
Inventor
니나 케이. 아라감
찰스 모리스
Original Assignee
래디어스 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 래디어스 파마슈티컬스, 인코포레이티드 filed Critical 래디어스 파마슈티컬스, 인코포레이티드
Publication of KR20210097170A publication Critical patent/KR20210097170A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217020321A 2018-11-30 2019-11-26 유방암을 갖는 여성에서 아베마시클립과 조합된 엘라세스트란트 Ceased KR20210097170A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862773960P 2018-11-30 2018-11-30
US62/773,960 2018-11-30
PCT/US2019/063239 WO2020112765A1 (en) 2018-11-30 2019-11-26 Elacestrant in combination with abemaciclib in women with breast cancer

Publications (1)

Publication Number Publication Date
KR20210097170A true KR20210097170A (ko) 2021-08-06

Family

ID=68966023

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217020321A Ceased KR20210097170A (ko) 2018-11-30 2019-11-26 유방암을 갖는 여성에서 아베마시클립과 조합된 엘라세스트란트

Country Status (18)

Country Link
US (3) US20220117963A1 (https=)
EP (1) EP3886826A1 (https=)
JP (2) JP2022509262A (https=)
KR (1) KR20210097170A (https=)
CN (1) CN113164415A (https=)
AU (1) AU2019388900B2 (https=)
BR (1) BR112021010169A2 (https=)
CA (1) CA3120368A1 (https=)
EA (1) EA202191165A1 (https=)
IL (1) IL283502A (https=)
JO (1) JOP20210125A1 (https=)
MA (1) MA54293A (https=)
MX (1) MX2021005876A (https=)
MY (1) MY209833A (https=)
PH (1) PH12021551235A1 (https=)
SG (1) SG11202105455RA (https=)
UA (1) UA129403C2 (https=)
WO (1) WO2020112765A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
EP4037768B1 (en) 2019-10-01 2023-10-11 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
AU2020399168A1 (en) 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
WO2022106711A1 (en) * 2020-11-23 2022-05-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN114146182A (zh) * 2021-11-12 2022-03-08 深圳大学 Cdk4/6抑制剂与铂类化疗药物在制备治疗肿瘤的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250152679A (ko) * 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
AU2017235450A1 (en) * 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
WO2018017410A1 (en) * 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer

Also Published As

Publication number Publication date
JOP20210125A1 (ar) 2019-11-26
EP3886826A1 (en) 2021-10-06
WO2020112765A1 (en) 2020-06-04
MA54293A (fr) 2021-10-06
BR112021010169A2 (pt) 2021-08-17
MY209833A (en) 2025-08-07
JP2025094216A (ja) 2025-06-24
CN113164415A (zh) 2021-07-23
SG11202105455RA (en) 2021-06-29
PH12021551235A1 (en) 2021-12-13
US20260014153A1 (en) 2026-01-15
EA202191165A1 (ru) 2021-09-21
AU2019388900B2 (en) 2025-09-04
CA3120368A1 (en) 2020-06-04
US20250268899A1 (en) 2025-08-28
AU2019388900A1 (en) 2021-06-10
JP2022509262A (ja) 2022-01-20
IL283502A (en) 2021-07-29
US20220117963A1 (en) 2022-04-21
MX2021005876A (es) 2021-07-16
UA129403C2 (uk) 2025-04-16

Similar Documents

Publication Publication Date Title
JP7516472B2 (ja) 癌を治療するための方法
US20250268899A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
RU2841076C2 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
RU2822195C2 (ru) Способы лечения рака на моделях, имеющих мутации esr1
US20250241875A1 (en) Methods for treating cancer in models harboring esr1 mutations
EA046925B1 (ru) Способы лечения рака на моделях, имеющих мутации esr1

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000